Jim Simons
AKTX

Jim Simons’s Akari Therapeutics AKTX Stock Holding History

Jim Simons’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-435
Closed -$20.4K – 3473
2025
Q2 		$20.4K Sell
435
-25
-5% -$1.26K ﹤0.01% 3469
2025
Q1 		$22.8K Sell
460
-127
-22% -$5.88K ﹤0.01% 3352
2024
Q4 		$28.6K Buy
587
+135
+30% +$10.2K ﹤0.01% 3457
2024
Q3 		$53.3K Buy
452
+25
+6% +$3.48K ﹤0.01% 3336
2024
Q2 		$46.1K Buy
427
+58
+16% +$4.28K ﹤0.01% 3303
2024
Q1 		$28K Buy
369
+112
+44% +$10.8K ﹤0.01% 3563
2023
Q4 		$32K Sell
257
-180
-41% -$23.8K ﹤0.01% 3517
2023
Q3 		$69K Buy
437
+39
+10% +$6.03K ﹤0.01% 3327
2023
Q2 		$54K Buy
398
+44
+12% +$6.36K ﹤0.01% 3600
2023
Q1 		$52K Buy
354
+285
+413% +$89.8K ﹤0.01% 3654
2022
Q4 		$26K Buy
69
+19
+38% +$7.86K ﹤0.01% 3912
2022
Q3 		$25K Sell
50
-7
-12% -$5.77K ﹤0.01% 3868
2022
Q2 		$46K Sell
57
-1
-2% -$887 ﹤0.01% 4007
2022
Q1 		$56K Sell
58
-17
-23% -$17.9K ﹤0.01% 3891
2021
Q4 		$90K Sell
75
-7
-9% -$9.03K ﹤0.01% 3699
2021
Q3 		$107K Sell
82
-107
-57% -$145K ﹤0.01% 3310
2021
Q2 		$262K Buy
189
+23
+14% +$36.8K ﹤0.01% 3183
2021
Q1 		$350K Buy
166
+31
+23% +$70.3K ﹤0.01% 3016
2020
Q4 		$199K Sell
135
-1
-0.7% -$1.39K ﹤0.01% 3141
2020
Q3 		$189K Sell
136
-31
-19% -$46K ﹤0.01% 3123
2020
Q2 		$291K Buy
167
+5
+3% +$7.62K ﹤0.01% 3052
2020
Q1 		$188K Sell
162
-53
-25% -$73.8K ﹤0.01% 3115
2019
Q4 		$301K Buy
215
+45
+26% +$66.3K ﹤0.01% 3069
2019
Q3 		$232K Buy
170
+1
+0.6% +$1.53K ﹤0.01% 3102
2019
Q2 		$273K Buy
169
+145
+604% +$324K ﹤0.01% 3206
2019
Q1 		$68K Buy
+24
New +$45.8K ﹤0.01% 3341

Other funds holding AKTX

CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
ACM
Accent Capital Management Centerville, Ohio $231M AUM 33.86% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Jim Simons's AKTX Position: Q3 2025 in Review

Jim Simons sold out of Akari Therapeutics (AKTX) in Q3 2025, closing a stake of 435 shares — an estimated $20.4K sold.

Jim Simons first reported a position in AKTX in Q1 2019 and held it in 26 quarters. The position peaked at $350K in Q1 2021. 14 funds tracked by Wall St. Rank hold AKTX as of Q3 2025.

  • Jim Simons reported no remaining Akari Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jim Simons sold 435 Akari Therapeutics shares in Q3 2025, an estimated $20.4K.
  • Jim Simons first reported a position in Akari Therapeutics in Q1 2019 and held it in 26 quarters.
  • Jim Simons's Akari Therapeutics position peaked at $350K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.